Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
This study is being conducted to determine the effectiveness of standard 3 weekly treatments using docetaxel and prednisone with metformin in patients with castration-resistant metastatic prostate cancer.

It is also being conducted to determine the levels of toxicity of metformin when added to every 3 weekly docetaxel treatments in patients with endocrine resistent, metastatic prostate cancer.
Prostate Cancer
DRUG: Metformin hydrochloride|DRUG: Docetaxel|DRUG: Prednisone
Measure efficacy, To determine the antitumor activity of metformin in combination with docetaxel and prednisone which are considered standard of care administered to patients with hormone refractory prostate cancer., 7 years
Measure toxicity, To evaluate the quantitative and qualitative toxicities of metformin with this schedule, in this population, 7 years
This is a single-arm, non-randomized Phase II trial of docetaxel given every 3 weeks with metformin twice daily and Prednisone twice daily. The study duration of this trial is open ended. The patient would take the metformin only for as long as they are treated with docetaxel.